Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Shahryar Khoshtinat Nikkhoi"'
Autor:
Ge Yang, Shahryar Khoshtinat Nikkhoi, Hajar Owji, Geng Li, Mohammad Massumi, Jessica Cervelli, Venu Gopal Vandavasi, Arash Hatefi
Publikováno v:
Antibodies, Vol 13, Iss 3, p 75 (2024)
We previously reported the structure, affinity, and anticancer activity of a bivalent bispecific natural killer cell engager (BiKE) composed of one anti-CD16a VHH and one anti-HER2 VHH fused via a linker. In this study, we explored the engineering of
Externí odkaz:
https://doaj.org/article/981b54c6cdbc4aadaae0bcc6fd76e634
Autor:
Ge Yang, Mohammad Massumi, Shahryar Khoshtinat Nikkhoi, Hajar Owji, Mayara Grizotte-Lake, Rick I Cohen, Lazaro Gil Gonzalez, Arash Hatefi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background In a prior report, we detailed the isolation and engineering of a bispecific killer cell engager, referred to as BiKE:E5C1. The BiKE:E5C1 exhibits high affinity/specificity for the CD16a activating receptor on natural killer (NK) cells and
Externí odkaz:
https://doaj.org/article/155b517c70c74416a35702828b6d5b6c
Autor:
Shahryar Khoshtinat Nikkhoi, Geng Li, Suha Eleya, Ge Yang, Venu Gopal Vandavasi, Arash Hatefi
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
IntroductionThe Fc region of monoclonal antibodies (mAbs) interacts with the CD16a receptor on natural killer (NK) cells with “low affinity” and “low selectivity”. This low affinity/selectivity interaction results in not only suboptimal antic
Externí odkaz:
https://doaj.org/article/4e03b9d20b4344a290532fab562b5b8d
Autor:
Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani, Fatemeh Rahbarizadeh, Shahryar Khoshtinat Nikkhoi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cel
Externí odkaz:
https://doaj.org/article/5ccb41937ea849e6b13379377d759270
Publikováno v:
Medical Oncology. 40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::accba0b1cbb0d4e656821e549303c56c
https://doi.org/10.1007/s12032-023-01975-1
https://doi.org/10.1007/s12032-023-01975-1
Publikováno v:
Medical Oncology. 39
CD20 is a receptor expressed on B cells with anonymous functions. The receptor is the target of some food and drug administration (FDA) approved monoclonal antibodies (mAb), such as Rituximab and Obinutuzumab. Blocking CD20 using the aforementioned m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b70fa381cb1db0d8c46d1308b87fbea
https://doi.org/10.1007/s12032-022-01757-1
https://doi.org/10.1007/s12032-022-01757-1
Autor:
Mortaza Taheri-Anganeh, Arad Aghaie Fard, Mehdi Tourani, Mohsen Mehdiabdol, Fatemeh Heydari, Hedieh Heydarzadeh, Seyyed Hossein Khatami, Shahryar Khoshtinat Nikkhoi
Publikováno v:
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 60(6)
The most promising therapy for leukemia is hematopoietic stem cell transplantation. Engraftment of HPSCs mainly depends on some factors such as adhesion molecules, including VLAs. This study tried to delineate the relationship between HPSCs engraftme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67432116bec1e244f97795ff48b5ea8f
https://pubmed.ncbi.nlm.nih.gov/34620563
https://pubmed.ncbi.nlm.nih.gov/34620563
Autor:
Davoud Ahmadvand, S. Reza Banihashemi, Shahryar Khoshtinat Nikkhoi, Fatemeh Rahbarizadeh, Ahmad Zavaran Hosseini
Publikováno v:
International immunopharmacology. 100
Objective One of the vital signaling pathways in cancer development and metastasis is mitogen-activated protein kinases (MAPKs). Bacillus anthracis Lethal Toxin (LT) is a potent MAPK signaling inhibitor. This toxin is comprised of two distinct domain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491e27b6cbd274d7a4e037b707db9ead
https://pubmed.ncbi.nlm.nih.gov/34500284
https://pubmed.ncbi.nlm.nih.gov/34500284
Publikováno v:
Nanotechnology in the Life Sciences ISBN: 9783030743291
Single-domain antibodies (VHHs), in particular those engineered from the variable heavy-chain fragment (VHH gene) found in Camelidae heavy-chain antibodies, are the smallest fragments that retain the full antigen-binding capacity of the antibody with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a13341c5d696449013c3bcc89ef6667
https://doi.org/10.1007/978-3-030-74330-7_4
https://doi.org/10.1007/978-3-030-74330-7_4
Publikováno v:
Recent patents on anti-cancer drug discovery. 16(4)
Objective:The aim of this study was to formulate fluorescent-labeled targeted immunoliposome to visualize the delivery and distribution of drugs in real-time.Methods:In this study, fluorescent-labeled liposomes were decorated with anti-HER2 VHH or He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ace59a20fa93121d74ffa5a443f83f
https://pubmed.ncbi.nlm.nih.gov/34365930
https://pubmed.ncbi.nlm.nih.gov/34365930